ADMA Biologics, Inc. (ADMA) Monday said that the United States Food and Drug Administration (FDA) has approved the company's innovative production yield enhancement process.
The company noted that the innovative process has shown an ability to increase production yields by about 20% from the same starting plasma volume.
"This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond," said Adam Grossman, President and Chief Executive Officer of ADMA.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.